Personalis, Inc.
Cancer genomics & liquid biopsy for early recurrence detection & guiding precision therapies.
PSNL | NDAQ
Overview
Corporate Details
- ISIN(s):
- US71535D1063
- LEI:
- Country:
- United States of America
- Address:
- 6600 DUMBARTON CIRCLE, 94555 FREMONT
- Website:
- https://www.personalis.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Personalis, Inc. is a cancer genomics company transforming cancer management through advanced testing and data science. The company's proprietary NeXT Platform® provides comprehensive molecular data by analyzing each patient's unique tumor. Its flagship offering, NeXT Personal®, is an ultra-sensitive, personalized liquid biopsy assay designed for the early detection of molecular residual disease (MRD) and cancer recurrence, often significantly earlier than standard imaging. Personalis partners with biopharmaceutical companies to support the development of next-generation precision therapies, including personalized cancer vaccines, and provides critical insights to clinicians to guide patient treatment strategies and improve outcomes.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Personalis, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Personalis, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Personalis, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
